|Mr. Michael S. Poirier||Chairman & CEO||742.28k||N/A||1956|
|Ms. Amy S. Broidrick||Pres, Chief Strategy Officer & Director||562.13k||N/A||1958|
|Mr. Tariq Arshad M.B.A., M.D.||Sr. VP & Chief Medical Officer||486.44k||N/A||1970|
|Mr. Christopher L. Lotz||VP of Fin. & CFO||N/A||N/A||1965|
|Mr. Shishir K. Sinha||COO, Corp. Sec. & Sr. VP of Diagnostics||N/A||N/A||1967|
|Dr. Wajdi Abdul-Ahad||VP of R&D and Chief Scientific Officer||N/A||N/A||1953|
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Qualigen Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.